Niacin, a form of vitamin B3, has shown promise as a potential treatment for Alzheimer’s disease based on recent research:
Researchers at the Indiana University School of Medicine found that niacin, when used in animal models, can limit the progression of Alzheimer’s disease.[1][2][3] They discovered that niacin interacts with a receptor called HCAR2 present in immune cells associated with amyloid plaques in the brain. Activating this receptor through niacin stimulates beneficial actions from these immune cells, leading to fewer plaques and improved cognition in the animal models.[1][2][3]
Past epidemiological studies have also suggested that people with higher levels of niacin in their diet have a lower risk of developing Alzheimer’s disease.[1][5] Additionally, niacin is currently being tested in clinical trials for other neurodegenerative diseases like Parkinson’s and glioblastoma.[1][2]
Based on these findings, researchers believe niacin is a promising therapeutic target for Alzheimer’s disease that warrants further clinical investigation. A pilot clinical trial is currently being planned to study the effects of niacin on the human brain.[1][2]
In summary, the available evidence indicates that niacin, an FDA-approved drug, may help modulate the immune response in the brain and slow the progression of Alzheimer’s disease. More research is needed, but niacin appears to be a potentially valuable therapeutic approach worth exploring.[1][2][3]
Citations:
[1] https://www.the-scientist.com/could-vitamin-supplementation-help-alzheimer-s-patients-69897
[2] https://medicine.iu.edu/news/2022/03/niacin-alzheimers-research
[3] https://www.sciencedaily.com/releases/2022/03/220323151716.htm
[4] https://atm.amegroups.org/article/view/101529/html
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1739176/